// App-Quantinova.ai

915 : Cytomegalovirus Reactivation After Allogeneic Stem Cell Transplantation Is Associated With a Reduced Risk Of Relapse In Patients With Acute Myeloid Leukemia: The Japan Society For Hematopoietic Cell Transplantation (JSHCT) Transplantation-Related Complication Working Group

Researchers

Presenter

  • Katsuto Takenaka

Principal Investigators

  • Tetsuya Nishida

  • Yuki Asano-Mori

  • Takuhiro Yamaguchi

  • Takahiro Fukuda

  • Kumi Oshima

  • Gaku Oshikawa

  • Koichi Miyamura

  • Tetsuya Eto

  • Hirohisa Nakamae

  • Hisashi Sakamaki

  • Yasuo Morishima

  • Ritsuro Suzuki

Medical Centers

  • Department of HSCT Data Management/Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan

  • Department of Hematology, Toranomon Hospital, Tokyo, Japan

  • Department of Medical Oncology, Hamanomachi Hospital, Fukuoka, Japan

  • Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital,

  • Department of Surgery and Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

  • Department of Pathologic Oncology, Mie University Graduate School of Medicine, Mie, Japan

  • Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

  • Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan

  • Department of Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

  • Hematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan

  • Division of Biostatistics, Tohoku University Hospital, Sendai, Japan

  • Hematology-Oncology Department, St Luke's International Hospital, Tokyo, Japan

  • Japanese Red Cross Nagoya First Hospital, Nagoya, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Alpha-thalassemia myelodysplasia syndrome

  • Chronic Myelogenous Leukemia

  • Acute myelocytic leukemia

  • Cytomegalovirus infection

  • Graft-versus-host disease

Biomarkers

  • Breakpoint Cluster Region

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved